Benefits of Detecting Brain Disease Early
One of the questions we hear most often is – Why early detect brain diseases when there is no cure? Read on.
A Brief History
We’ve been officially at war with brain diseases for ages! How long?
- Lewy Body Dementia (LBD) was named in 1976,
- Alzheimer’s in 1906
- Parkinson’s was in 1817
That’s over 200 years (or eight generations if you’re into genealogy).
Of course, we’re not even counting the previous centuries when brain diseases namelessly devastated human lives.
So, have we been fighting hard?
Research efforts so far
Spending
In 2019, the National Institute of Health (NIH) spent:
- $66 million on LBD research
- $224 million on Parkinson’s research
- $2.4 billion (yes, with a “B”) on Alzheimer’s research
Clinical Trials
As of April 2021, there have been:
LBD
- 131 clinical trials in various stages
Alzheimer’s
- 2,574 clinical trials in various stages
Parkinson’s
- 2,891 clinical trials in various stages
Bottom Line:
What did we get for our three decades of hard work and $100 billion in brain disease drug development?
Zilch.
We have no cure so far.
To turn the tide, we invented biomarker testing for brain diseases.
What Makes Biomarker Testing a Game-Changer?
Knowing Empowers.
It puts you in control to navigate your brain care journey and helps advance science for personalized medicine.
It puts you in control to navigate your brain care journey and helps advance science for personalized medicine.
Thanks to scientific innovation, our SYNTapⓇ Biomarker Test can help. Alongside other diagnostic tools, doctors can now employ the SYNTap Test for diagnosing Lewy Body Dementia, Parkinson’s, and other brain diseases.
Biomarker testing is the keystone for personalized medicine.
How our technology helps advance drug development for brain diseases.
Early Prevention Is Key.
According to the Alzheimer’s Association, by delaying the onset of Alzheimer’s just 5 years, the number of people affected plummets 42%.
